1. |
Thigpena JT, Aghajanianb CA, Albertsc DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic Oncology, 2005; 68(96): 10–18.
|
2. |
Latorre A, De Lena M, Catino A, et al. Epithelial ovarian cancer-second and third line chemotherapy (review). Int J Oncol, 2002; 21(6): 179–186.
|
3. |
Ozols R.F, Update on the management of ovarian cancer. Cancer, 2002; 8(suppl 1): S22–30.
|
4. |
Gadducci A, Sartore E, Maggino T, et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian Multicenter study. Gynecol Oncol, 1998; 68(156): 150–155.
|
5. |
Swenerton K, Muss HB, Robinson EG. Salvage chemotherapy for refractory disease. In: Gershenson DM, McGuire WP: Ovarian cancer controversies on management. NY, Charchill livingstone, 1998: P169–194.
|
6. |
Parazzini F, Raspagliesi F, Guarnerio P, et al. Role of secondary surgery in relapsed ovarian cancer. Cri Rer Oncol Hematol, 2001; 32(25): 121–125.
|
7. |
Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002; 7(suppl 5): 20–28.
|
8. |
National Institute for Clinical Excellence: Final Appraisal Determination. Ovarian cancer (advanced): topotecan, pegylated liposomal doxorubicin hydrochloridn and paclitaxel. NICE. March 2005.
|
9. |
Rustin GJS, Nelstrop ARE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. Clin Oncol, 1996; 14(5): 1545–1551.
|
10. |
Rustin GJS, Nelstrop ARE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125. Clin Oncol, 1997; 15(1): 172–176.
|
11. |
Martin Gore, Wim ten Bokkel Huinink, James Carmichael, et al. Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer. Clin Oncol, 2001; 19(7): 1893–1900.
|
12. |
Gordon-AN, Fleagle-JT, Guthrie-D, et al. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan. Clinical Oncology, 2001; 19(14): 3312–3322.
|
13. |
Smith DH, Adams JR, Johnston SR, et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol, 2002; 13(10):.
|
14. |
Cohen J: A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 1960; 20(42): 37–46.
|
15. |
Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affectestimates of intervention efficacy reported in meta-analyses. Lancet, 1998; 352(9128): 609–613.
|
16. |
Gordon AN,Tonda M,Sun S, et al. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol, 2004; 95(1): 1–8.
|
17. |
Capri S, Cattaneo G. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clin Ther, 2003; 25(6): 1826–1845.
|
18. |
Ojeda B, de Sande LM, Casado A, et al. Cost-minisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br. J Cancer, 2003; 89(6): 1002–1007.
|
19. |
Ten Bokkel Huinink W, Lane SR, Ross GA, et al. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of oncology, 2004; 15(1): 100–103.
|
20. |
Ten Bokkel Huinink W, Gore M, Carminchael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Clinical Oncology, 1997; 15(6): 2183–2193.
|
21. |
Hoskins P, Eisenhauer E, Beare S, et al. Randomized Phase II Study of Two Schedules of Topotecan in Previously Treated Patients With Ovarian Cancer: A National Cancer Institute of Cancer Institute of Canada Clinical Trials Group Study. Clin Oncol, 1998; 16(6): 2233–2237.
|
22. |
M Gore, A Ozab, G Rustinc, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur. J Cancer, 2002; 38(32): 57–63.
|
23. |
Markman M, Kennedy A, Webster K, et al. Phase 2 evaluation of topotecan administered on a 3-days schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol, 2000; 7766: 116–119.
|
24. |
Levya T, Inbarb M, Menczera J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol, 2004; 95(186): 686–690.
|
25. |
Johnson S, Pyle l, King K, et al. A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma. Eur J Cancer, 1997; 58(78): abstr 537.
|
26. |
–1597.
|